Financial Analysis: Standard BioTools Inc (LAB)’s Ratios Unveil Key Insights

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Standard BioTools Inc’s stock clocked out at $1.60, down -1.23% from its previous closing price of $1.62. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 1.42 million shares were traded. LAB stock price reached its highest trading level at $1.67 during the session, while it also had its lowest trading level at $1.575.

Ratios:

To gain a deeper understanding of LAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.

On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.

On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Black Jeffrey G. bought 57,971 shares for $2.12 per share.

Taich Adam bought 45,851 shares of LAB for $91,725 on Sep 09 ’24. On Aug 27 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $2.19 each. As a result, the insider paid 546,750 and bolstered with 54,025,821 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 595614400 and an Enterprise Value of 205840192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.77 while its Price-to-Book (P/B) ratio in mrq is 1.22. Its current Enterprise Value per Revenue stands at 1.32 whereas that against EBITDA is -1.801.

Stock Price History:

Over the past 52 weeks, LAB has reached a high of $3.04, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is -14.61%, while the 200-Day Moving Average is calculated to be -26.91%.

Shares Statistics:

It appears that LAB traded 1.88M shares on average per day over the past three months and 2356350 shares per day over the past ten days. A total of 372.26M shares are outstanding, with a floating share count of 360.19M. Insiders hold about 3.24% of the company’s shares, while institutions hold 75.14% stake in the company. Shares short for LAB as of 1730332800 were 19540970 with a Short Ratio of 10.40, compared to 1727654400 on 21293767. Therefore, it implies a Short% of Shares Outstanding of 19540970 and a Short% of Float of 10.780000000000001.

Most Popular